Lisa Su Says AMD Will Pay Trump's 15% Fee To Resume China AI Chip Sales Despite Beijing's Partial Block On Foreign Silicon

AMD said it is prepared to restart shipments of its MI308 AI chips to China after securing U.S. export licenses and will comply with a 15% export fee, according to CEO Lisa Su. The move mitigates downside to China revenue — which AMD previously said could be reduced by roughly $800 million if access were lost — and follows stronger-than-expected Q3 results ($9.25 billion revenue) and Q4 sales guidance of about $9.6 billion excluding China. Management highlighted a multiyear OpenAI GPU supply deal that could generate more than $100 billion starting in 2026, while the stock is up ~79% YTD and traded around $216.20 in after-hours.

Analysis

Market structure: Restored MI308 exports (with a 15% fee) mechanically restores a revenue bucket (~$0.8bn annualized risk if lost) and reduces China-induced downside for AMD (AMD). Short-term demand in China will be bifurcated: state-funded projects pivot to domestic chips while private cloud and hyperscalers still buy US silicon. Expect modest price discipline on high-end datacenter GPUs — incumbents (AMD, NVDA) retain pricing power for next 12–24 months but face segmented volume recovery in China.

Risk assessment: Tail risks include rapid re-tightening of US export licenses, a China full ban on foreign chips in state projects (probability 15–25% in 12 months), or sanctions that block supply of key components. Immediate (days) risk = volatility on licensing headlines; short-term (weeks–months) risk = guidance revisions; long-term (2026+) risk = execution against the OpenAI Instinct GPU ramp. Hidden dependency: AMD’s revenue mix and margin sensitivity to a 15% export tariff — fee passes to buyers only partially, pressuring gross margin by ~200–400bps on China sales.

Trade implications: Tactical: establish a 2–3% long position in AMD shares as asymmetric exposure to China-licensing normalization and OpenAI ramp; hedge with a 1–1.5% short NVDA position if funding concerns or valuation mean-reversion risk is preferred. Options: buy a 6–12 month AMD call spread (buy ATM, sell 20–30% OTM) to cap cost and target >20–40% upside; sell a covered-call against new long if shares rally >25%.

Contrarian angles: Consensus treats China access as binary; reality is fractional flows and margin leakage from the 15% fee. Market may underprice the OpenAI partnership (>$100bn multi-year potential starting 2026) while overpricing near-term China fragility. If Commerce approvals cluster within 30–60 days, rapid re-rating could occur; conversely, incremental restrictions would be a buying opportunity for long-term exposure under 12–18 month horizon.

Key Decisions for Investors

• Establish a 2–3% long position in AMD (NASDAQ:AMD) sized to portfolio risk within 2 weeks; set tactical stop-loss at -12% and take-profit tranche at +25% (sell 50% of position if hit).
• Implement a hedged pair: long AMD 2% and short NVDA (NASDAQ:NVDA) 1–1.5% to isolate China/valuation delta; close short if NVDA underperforms by >15% relative to AMD over 60 days.
• Buy a 6–12 month AMD call spread (buy ATM call, sell 20–30% OTM call) sized equal to 25–50% of the cash position to target 30–40% net return while limiting premium outlay; unwind if MI308 license approval rate by US Commerce >50% within 30 days.
• If uncertain about regulatory path, sell near-term (30–60 day) covered calls at ~+10% OTM on existing AMD exposure to collect premium and reduce effective cost basis, rolling if shares gap higher.
• Reduce/avoid incremental exposure to China-focused local AI chip suppliers (private/state-backed) and reallocate 1–3% portfolio weight into diversified datacenter plays (SMH or AMZN/GOOGL cloud exposure) to capture non-China hyperscaler demand through 2026.